| Board members |
|
|
B.Sc. in Mechanical Engineering
Chairman of the Board
Previously Managing Director of Medtronic Denmark, several international positions at Medtronic, Managing Director of NKT Comcab S.A., Portugal.
Member of the board of Neurodan A/S and Vivolution A/S, both Denmark.
M.D., Ph.D., Professor in Orthopaedics at the University Hospital of Lund
Founder of BoneSupport AB.
Scientific Board member at the National Board of Health and Welfare and member of the Editorial Board of JBJS. Lidgren initiated the worldwide Bone and Joint Decade 2000-2010. Chairman of the International Steering Committee of the Bone and Joint Decade. Founder of the companies Ultrazonix AB and Scandimed AB.
M.Sc. Economics and Business Administration
Partner, Teknoinvest Management AS. Former Managing Director of Nycomed Pharma, Medical Equipment.
Chairman of the board of SantoSolve AS and Silva AS, both Norway. Member of the board of Vensafe ASA (Norway) and Mison AS (Norway). Observer at the board of Inovio Biomedicla Corp. (USA). Chairman of the Corporate Assembly of Peterson Linerboard AS (Norway).
A founding partner of HealthCap. Dr Odlander is a Medical Doctor and was previously a member of ABB Aros Management Committee and headed the Aros Health Care Team. Prior to joining Aros in 1992, Dr Odlander was active at the Karolinska Institute, Stockholm, Sweden. In addition to teaching medical students, he pursued scientific research in the biochemistry of inflammation. Dr. Odlander serves on the boards of the following companies: Affibody, Biolipox, Biotage, LTB4, Jerini and OxThera.
Investment Manager, NBGI Ventures
Investment Manager at NBGI Ventures, a European venture capital fund investing in medical technology companies. John has 15 years’ experience in international venture capital and finance. Previously he was a Special Advisor to Atlas Venture, Interim CFO and Head of Business Development at Nitec Pharma AG, Founder of Insight Capital & Advisory and an Associate Director at Nomura International plc, having started his career in New York at Lehman Brothers and Kirkland Investors. John holds a BA in Political Science from University of Chicago.
Director
Currently President, CEO, and Director of Pulmonx
Previously President, CEO, and Director of ArthroCare Corporation; several executive and general management positions at Medtronic, Inc.; and Member of the board at Conceptus, Inc., ProDuct Health, and Synectics Medical AB.
| Deputy board members |
|
|
M.Sc. in economics and business administration, Authorised Financial Analyst
Executive Vice President, Ferd Venture, previously Deloitte & Touche.
Member of the board in Nacre and Teknoinvest VII. Member of the Board and Chairman of the Investment Committee in Energy Ventures I & II.
B.Sc. Political Sciences, Chartered Financial Analyst
Co-Founder and Senior Partner of Vencorp Partners, whose inaugural Private Equity Fund focus its investments on the problematic of an ageing population in Europe.
Previously held senior positions at UBS and affiliates.
In 1996 founded his own Asset Management company.
B.Sc. Economics and Business Administration
Mr Fredrikson is a founding partner of Health Cap and the President of Odlander Fredrikson S.A. He was previously a member of ABB Aros Management Committee and was responsible for Aros’ corporate finance and private equity businesses. He has been active in international investment banking since the late 1970s. Prior to joining Aros in 1993, Mr. Fredrikson was a Managing Director of Dillon Read & Co Inc, in charge of Dillon Read’s Scandinavian investment banking practice. Previously, he was a Managing Director of Prudential Bache Capital Funding, having also been associated with Morgan Stanley, Smith Barney and Bank of America.
B.Eng Mechanical Engineering - Imperial College; MS, Mechanical Engineering - MIT; MBA - Insead
Co-founder and partner at NBGI Ventures, a European venture capital fund investing in medical technology companies. Aris has more than 10 years venture capital and private equity experience, previously with Deutsche Bank’s and Credit Suisse First Boston’s VC funds.
